Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Wladimir Correa Taborda"
We found (3) results for your search.Summary
Rev Bras Ginecol Obstet. 1998;20(3):161-163
DOI 10.1590/S0100-72031998000300007
A tocolytic treatment is described with the use of terbutaline in a case of cardiotocographic prolonged deceleration of fetal heart rate with successful outcome.
Summary
Rev Bras Ginecol Obstet. 1998;20(3):161-163
DOI 10.1590/S0100-72031998000300007
A tocolytic treatment is described with the use of terbutaline in a case of cardiotocographic prolonged deceleration of fetal heart rate with successful outcome.
Summary
Rev Bras Ginecol Obstet. 2003;25(4):277-281
DOI 10.1590/S0100-72032003000400009
PURPOSE: the aim of the present study was to evaluate the accuracy of microalbuminuria to predict preeclampsia. METHODS: a prospective study of 45 consecutive diabetic gestations that were tested for microalbuminuria before the 18th week, between the 18th and 24th week and between the 32nd and 36th week of gestation. All patients had their prenatal care done from January 2000 to December 2001. The DCA 2000 microalbumin/creatinine assay is a quantitative method for measuring low concentrations of albumin, creatinine and the albumin/creatinine ratio in urine. According to laboratory standards, an albumin/creatinine ratio >16 mg/g (1.8 mg/mmol) indicates incipient renal damage and risk for preeclampsia. The sensitivity, specificity, positive and negative predictive values of the albumin/creatinine ratio were determined to predict the occurrence or the absence of preeclampsia, diagnosed through clinical criteria. RESULTS: of all patients, 17% developed preeclampsia. The sensitivity of albumin/creatinine ratio increased from 12.5% at 18 weeks to 25% between the 18th and 24th week and to 87% after the 32nd week. On the other hand, specificity presented a decreasing value from 97 to 89 and 83%, respectively). The positive predictive value was relatively low in the three different periods of evaluation (50, 33 and 53%, respectively. The negative predictive value was increased in the three stages of gestational age (83, 84 and 96%, respectively). CONCLUSIONS: quantification of microalbuminuria could correctly predict the absence of preeclampsia but was less accurate to predict the occurrence of the disease in diabetic pregnancies.
Summary
Rev Bras Ginecol Obstet. 2003;25(4):277-281
DOI 10.1590/S0100-72032003000400009
PURPOSE: the aim of the present study was to evaluate the accuracy of microalbuminuria to predict preeclampsia. METHODS: a prospective study of 45 consecutive diabetic gestations that were tested for microalbuminuria before the 18th week, between the 18th and 24th week and between the 32nd and 36th week of gestation. All patients had their prenatal care done from January 2000 to December 2001. The DCA 2000 microalbumin/creatinine assay is a quantitative method for measuring low concentrations of albumin, creatinine and the albumin/creatinine ratio in urine. According to laboratory standards, an albumin/creatinine ratio >16 mg/g (1.8 mg/mmol) indicates incipient renal damage and risk for preeclampsia. The sensitivity, specificity, positive and negative predictive values of the albumin/creatinine ratio were determined to predict the occurrence or the absence of preeclampsia, diagnosed through clinical criteria. RESULTS: of all patients, 17% developed preeclampsia. The sensitivity of albumin/creatinine ratio increased from 12.5% at 18 weeks to 25% between the 18th and 24th week and to 87% after the 32nd week. On the other hand, specificity presented a decreasing value from 97 to 89 and 83%, respectively). The positive predictive value was relatively low in the three different periods of evaluation (50, 33 and 53%, respectively. The negative predictive value was increased in the three stages of gestational age (83, 84 and 96%, respectively). CONCLUSIONS: quantification of microalbuminuria could correctly predict the absence of preeclampsia but was less accurate to predict the occurrence of the disease in diabetic pregnancies.
Summary
Rev Bras Ginecol Obstet. 2000;22(9):543-549
DOI 10.1590/S0100-72032000000900002
Purpose: to compare the efficiency between magnesium sulfate and phenytoin in the control of convulsions in patients with eclampsia and to evaluate the effects of magnesium sulfate and phenytoin on the maternal and perinatal prognosis in patients with eclampsia. Methods: this is a prospective, randomized and controlled study in which the results obtained with the use of anticonvulsive treatment in 77 women with eclampsia, treated with either magnesium sulfate or phenytoin, were analyzed comparatively. The drugs which were used in both therapeutic schemes were distributed in a one to one ratio, in randomly numbered boxes which presented similar characteristics. When a patient was admitted, a box was opened and its contents were given to the patient. Results: in the group whose patients were treated with magnesium sulfate, 19.5% had recurrent convulsions while in the group whose patients used phenytoin, 36.1% had new crises (p<0,05). The patients who were treated with magnesium sulfate showed a greater prevalence of postpartum hemorrhage (14,7%) than those to whom phenytoin was administered (2.7%) (p<0.05). In relation to the newborns, 17.0% of the group from mothers treated with magnesium sulfate presented respiratory distress as opposed to the group of newborns from mothers treated with phenytoin (11.8%), (p> 0,05). Conclusion: magnesium sulfate is shown to be more efficient than phenytoin in the control and the prevention of convulsions in patients with eclampsia. However, its utilization showed a higher prevalence of postpartum hemorrhage and respiratory distress. Phenytoin should be used in cases where the use of magnesium sulfate is contraindicated.
Summary
Rev Bras Ginecol Obstet. 2000;22(9):543-549
DOI 10.1590/S0100-72032000000900002
Purpose: to compare the efficiency between magnesium sulfate and phenytoin in the control of convulsions in patients with eclampsia and to evaluate the effects of magnesium sulfate and phenytoin on the maternal and perinatal prognosis in patients with eclampsia. Methods: this is a prospective, randomized and controlled study in which the results obtained with the use of anticonvulsive treatment in 77 women with eclampsia, treated with either magnesium sulfate or phenytoin, were analyzed comparatively. The drugs which were used in both therapeutic schemes were distributed in a one to one ratio, in randomly numbered boxes which presented similar characteristics. When a patient was admitted, a box was opened and its contents were given to the patient. Results: in the group whose patients were treated with magnesium sulfate, 19.5% had recurrent convulsions while in the group whose patients used phenytoin, 36.1% had new crises (p<0,05). The patients who were treated with magnesium sulfate showed a greater prevalence of postpartum hemorrhage (14,7%) than those to whom phenytoin was administered (2.7%) (p<0.05). In relation to the newborns, 17.0% of the group from mothers treated with magnesium sulfate presented respiratory distress as opposed to the group of newborns from mothers treated with phenytoin (11.8%), (p> 0,05). Conclusion: magnesium sulfate is shown to be more efficient than phenytoin in the control and the prevention of convulsions in patients with eclampsia. However, its utilization showed a higher prevalence of postpartum hemorrhage and respiratory distress. Phenytoin should be used in cases where the use of magnesium sulfate is contraindicated.